All patients who enroll will receive C134 inoculation into their tumor (one time procedure with 1-5 inoculation sites)

Glioblastoma Multiforme of Brain

Anaplastic Astrocytoma of Brain

Gliosarcoma of Brain

C134 is a virus that was created from an oncolytic Herpes Simplex Virus (oHSV) known to infect and kill tumor cells. The Investigators have made changes to the original virus to make C134. It efficiently infects tumor cells (not normal healthy cells) and induces an immune response to fight the cancer as well.

C134

University of Alabama at Birmingham

Trial of C134 in Patients With Recurrent GBM

A Phase I Trial of IRS-1 HSV C134 Administered Intratumorally in Patients With Recurrent Malignant Glioma

Adverse events will be monitored and any changes in status will be recorded for each patient as outlined in CTCAE v4.0 reporting requirements.

Patients will receive contrast-enhanced MRI to monitor progression (changes in tumor volume or tumor enhancement assessed by the iRANO criteria). As indicated in the criteria, biopsy and/or resection may be performed in instances of uncertainty. Determination of time to progression (in months) will be recorded for each patient and median progression-free survival will be calculated for the entire cohort (Kaplan-Meier).

Patients survival will be recorded (Kaplan-Meier).

Detection and quantification of HSV antibody titer via ELISA, pfu/mL.

White blood cell subset analysis by FACS, as a percent of total white blood cell number.

Intracellular lymphocyte interferon levels will be assessed by FACS analysis ng/mL

James Markert, MD

Principal Investigator

Gateway for Cancer Research

National Cancer Institute (NCI)

Modified continuous reassessment model (mCRM). Using this statistical method, dose changes occur based upon toxicities (or lack thereof) observed after a 24 day observation period for the initial dose level. If toxicities occurring at any dose were acceptable, doses for subsequent cohorts can be increased by up to 1 log until a maximum tolerated dose is reached. If toxicities are unacceptable then dose de-escalation occurs until a safe acceptable maximum tolerated dosage is defined. However, it should be noted that the dose alterations are not predictable and cannot be predefined, they are statistically determined after each patient using mCRM software.

Docetaxel (1000mg PO BID days 5-18 of each Cycle) and Capecitabine (30mg/m2/week IV days 1, 8, &15)

Docetaxel (1000mg PO BID days 5-18 of each Cycle) and Capecitabine (30mg/m2/week IV days 1, 8, &15)
Docetaxel: Each four-week cycle consists of three infusions through a vein of docetaxel, on days 1, 8, and 15. If the subject's disease has decreased significantly, he/she will continue to receive docetaxel on the every four-week schedule.
Capecitabine: Each four-week cycle consists of fourteen days of a medication that the subject will take two times a day orally, on days 5-18. If the subject's disease has decreased significantly, he/she will continue to receive docetaxel on the every four-week schedule.

Arm 1

Sex: Female, Male

Race (NIH/OMB)

Region of Enrollment

The Eastern Cooperative Oncology Group (ECOG) Performance Status score is an attempt to quantify a cancer patients' general well-being and activities of daily life. It runs from 0 to 5, with 0 denoting perfect health and 5 death

Eastern Cooperative Oncology Group (ECOG) Performance Status

Histology

Disease Extent

Disease was assessed by radiologic imaging and RECIST (Response Evaluation Criteria in Solid Tumors) was used to determine response: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

Overall Response Rate at 4 Months

The frequency of grade 3 and grade 4 adverse events experienced by all treated participants.

Frequency of Grade III/IV Toxicities Experienced by Participants

The estimated 1 year progression free survival. Progression was defined, using RECIST (Response Evaluation Criteria In Solid Tumors Criteria), as a 20% increase in the sum of the longest diameter of target lesions, the development of any new lesion, or the significant clinical deterioration related to the progression of patient's disease. The probability of progression-free survival was presented in a Kaplan-Meier curve to illustrate the distribution of progression time. The median time to progression was determined with a 95% CI (Confidence Interval).

Probability of Progression Free Survival

Docetaxel and Capecitabine

Overall Study

Dr. Francis Worden

Head and Neck Cancer

Each four-week cycle consists of three infusions through a vein of docetaxel, on days 1, 8, and 15. If the subject's disease has decreased significantly, he/she will continue to receive docetaxel on the every four-week schedule. If the subject's disease has not decreased significantly but there is no evidence the disease is getting worse, he/she will continue on the same treatment until: a) there is evidence that the treatment is no longer working to control the growth of his/her disease, b) He/she experiences unacceptable toxicity, c) his/her disease progresses, or d) he/she chooses to stop therapy.

Docetaxel

Each four-week cycle consists of fourteen days of a medication that the subject will take two times a day orally, on days 5-18. If the subject's disease has decreased significantly, he/she will continue to receive docetaxel on the every four-week schedule. If the subject's disease has not decreased significantly but there is no evidence the disease is getting worse, he/she will continue on the same treatment until: a) there is evidence that the treatment is no longer working to control the growth of his/her disease, b) He/she experiences unacceptable toxicity, c) his/her disease progresses, or d) he/she chooses to stop therapy.

thymidine/پوسیدگی دندان

Trial of C134 in Patients With Recurrent GBM

A Study of a New Combination and Schedule of Chemotherapy Drugs for the Treatment of Head and Neck Cancer

کاملترین پایگاه داده گیاهان دارویی با پشتیبانی علمی